Qiagen N.V. (QGEN) Shares Sold by First Mercantile Trust Co.
First Mercantile Trust Co. decreased its stake in shares of Qiagen N.V. (NASDAQ:QGEN) by 2.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 14,173 shares of the company’s stock after selling 420 shares during the period. First Mercantile Trust Co.’s holdings in Qiagen N.V. were worth $476,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in the stock. FNY Managed Accounts LLC purchased a new position in Qiagen N.V. during the first quarter valued at $103,000. Oppenheimer Asset Management Inc. purchased a new position in Qiagen N.V. during the first quarter valued at $114,000. Rehmann Capital Advisory Group purchased a new position in Qiagen N.V. during the first quarter valued at $207,000. Prudential Financial Inc. purchased a new position in Qiagen N.V. during the first quarter valued at $207,000. Finally, Quantitative Systematic Strategies LLC purchased a new position in Qiagen N.V. during the second quarter valued at $211,000. 60.07% of the stock is currently owned by hedge funds and other institutional investors.
Qiagen N.V. (NASDAQ QGEN) opened at 31.36 on Wednesday. The stock has a market capitalization of $7.16 billion, a price-to-earnings ratio of 95.90 and a beta of 1.14. Qiagen N.V. has a 12-month low of $24.86 and a 12-month high of $35.26. The firm has a 50-day moving average of $33.21 and a 200 day moving average of $31.25.
Qiagen N.V. (NASDAQ:QGEN) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The business had revenue of $349 million for the quarter, compared to analyst estimates of $353.09 million. During the same period last year, the business earned $0.24 EPS. The company’s revenue was up 4.4% on a year-over-year basis. On average, analysts predict that Qiagen N.V. will post $1.23 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/qiagen-n-v-qgen-shares-sold-by-first-mercantile-trust-co/1493975.html.
QGEN has been the topic of several research analyst reports. TheStreet raised Qiagen N.V. from a “c” rating to a “b” rating in a report on Monday, June 5th. Commerzbank Ag reissued a “buy” rating on shares of Qiagen N.V. in a report on Tuesday, June 6th. Barclays PLC reissued a “buy” rating and set a $33.00 price target on shares of Qiagen N.V. in a report on Monday, May 15th. Deutsche Bank AG restated a “buy” rating on shares of Qiagen N.V. in a research report on Tuesday, May 2nd. Finally, BidaskClub lowered Qiagen N.V. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 10th. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $33.17.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NASDAQ:QGEN).
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.